Epidermolysis Bullosa - Pipeline Review, H2 2017

  • ID: 4410086
  • Report
  • 106 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abeona Therapeutics Inc
  • Amryt Pharma plc
  • Berg LLC
  • Exicure Inc
  • GlaxoSmithKline Plc
  • InMed Pharmaceuticals Inc
  • MORE
Epidermolysis Bullosa - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa - Pipeline Review, H2 2017, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.

Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 1, 11 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abeona Therapeutics Inc
  • Amryt Pharma plc
  • Berg LLC
  • Exicure Inc
  • GlaxoSmithKline Plc
  • InMed Pharmaceuticals Inc
  • MORE
Introduction

REPORT COVERAGE

Epidermolysis Bullosa - Overview

Epidermolysis Bullosa - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Epidermolysis Bullosa - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Epidermolysis Bullosa - Companies Involved in Therapeutics Development

Abeona Therapeutics Inc

Almirall SA

Amryt Pharma plc

Anterogen Co Ltd

Berg LLC

CSL Ltd

Exicure Inc

Fibrocell Science Inc

GlaxoSmithKline Plc

Immusoft Corp

InMed Pharmaceuticals Inc

Mesoblast Ltd

ProQR Therapeutics NV

RegeneRx Biopharmaceuticals Inc

Stratatech Corp

TransDerm Inc

WAVE Life Sciences Ltd

Epidermolysis Bullosa - Drug Profiles

AC-203 - Drug Profile

ADP-31415 - Drug Profile

Antisense Oligonucleotide 1 to Inhibit Keratin for Epidermolysis Bullosa Simplex - Drug Profile

Antisense Oligonucleotide 2 to Inhibit Keratin for Epidermolysis Bullosa Simplex - Drug Profile

Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa - Drug Profile

Biologic for Epidermolysis Bullosa - Drug Profile

birch bark extract - Drug Profile

Cell Therapy for Dermatology and Immunology - Drug Profile

Cell Therapy for Epidermolysis Bullosa - Drug Profile

diacerein - Drug Profile

EB-101 - Drug Profile

EB-201 - Drug Profile

FCX-007 - Drug Profile

Gene Therapy for Epidermolysis Bullosa - Drug Profile

Gene Therapy to Activate COL7A1 for Epidermolysis Bullosa - Drug Profile

Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile

HOLOGENE-17 - Drug Profile

ICX-RHY - Drug Profile

INM-750 - Drug Profile

ISN-001 - Drug Profile

KB-103 - Drug Profile

M-230 - Drug Profile

Protein to Target COL7A1 for Epidermolysis Bullosa - Drug Profile

QRX-313 - Drug Profile

QRX-323 - Drug Profile

remestemcel-L - Drug Profile

RGN-137 - Drug Profile

sirolimus - Drug Profile

Stem Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile

TXA-127 - Drug Profile

ubidecarenone - Drug Profile

Epidermolysis Bullosa - Dormant Projects

Epidermolysis Bullosa - Discontinued Products

Epidermolysis Bullosa - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Epidermolysis Bullosa, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Companies, H2 2017 (Contd..1), H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Epidermolysis Bullosa - Pipeline by Abeona Therapeutics Inc, H2

Epidermolysis Bullosa - Pipeline by Almirall SA, H2

Epidermolysis Bullosa - Pipeline by Amryt Pharma plc, H2

Epidermolysis Bullosa - Pipeline by Anterogen Co Ltd, H2

Epidermolysis Bullosa - Pipeline by Berg LLC, H2

Epidermolysis Bullosa - Pipeline by CSL Ltd, H2

Epidermolysis Bullosa - Pipeline by Exicure Inc, H2

Epidermolysis Bullosa - Pipeline by Fibrocell Science Inc, H2

Epidermolysis Bullosa - Pipeline by GlaxoSmithKline Plc, H2

Epidermolysis Bullosa - Pipeline by Immusoft Corp, H2

Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc, H2

Epidermolysis Bullosa - Pipeline by Mesoblast Ltd, H2

Epidermolysis Bullosa - Pipeline by ProQR Therapeutics NV, H2

Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals Inc, H2

Epidermolysis Bullosa - Pipeline by Stratatech Corp, H2

Epidermolysis Bullosa - Pipeline by TransDerm Inc, H2

Epidermolysis Bullosa - Pipeline by WAVE Life Sciences Ltd, H2

Epidermolysis Bullosa - Dormant Projects, H2

Epidermolysis Bullosa - Discontinued Products, H2

List of Figures

Number of Products under Development for Epidermolysis Bullosa, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Top 10 Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abeona Therapeutics Inc
  • Almirall SA
  • Amryt Pharma plc
  • Anterogen Co Ltd
  • Berg LLC
  • CSL Ltd
  • Exicure Inc
  • Fibrocell Science Inc
  • GlaxoSmithKline Plc
  • Immusoft Corp
  • InMed Pharmaceuticals Inc
  • Mesoblast Ltd
  • ProQR Therapeutics NV
  • RegeneRx Biopharmaceuticals Inc
  • Stratatech Corp
  • TransDerm Inc
  • WAVE Life Sciences Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll